biosimilars

News

Generics group says VPAG may lead to shortages

Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufac

News

Biogen claims first with FDA nod for biosimilar Actemra

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra.

News

Polpharma Bio gets first EU okay for Tysabri biosimilar

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.

R&D

The SPC waiver: How do we restore the intended balance betwe...

Biosimilars promote cost-effective solutions to critical healthcare challenges.

News

EU has its first RoActemra biosimilar, from Fresenius Kabi

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi.

News

Novartis updates on Sandoz finances ahead of spin-off

Novartis confirmed this morning that it expects to complete the separation of its generic and biosimilar medicines unit Sandoz into an independent company on or around 4th

Generics group says VPAG may lead to shortages

Biogen claims first with FDA nod for biosimilar Actemra

Polpharma Bio gets first EU okay for Tysabri biosimilar

The SPC waiver: How do we restore the intended balance betwe...

EU has its first RoActemra biosimilar, from Fresenius Kabi

Novartis updates on Sandoz finances ahead of spin-off

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

biosimilars

Editor's Picks